218797-72-9 Usage
Uses
Used in Pharmaceutical Industry:
4-bromo-2-chloro-6-fluoroBenzonitrile serves as a crucial intermediate in the synthesis of pharmaceutical compounds. Its unique structure and reactivity contribute to the development of new drugs, enhancing the range of treatments available for various medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-2-chloro-6-fluoroBenzonitrile is utilized as an intermediate for the production of agrochemicals. Its role in creating effective pesticides and other agricultural products helps improve crop protection and yield.
Used in Dye Production:
4-bromo-2-chloro-6-fluoroBenzonitrile acts as a building block in the creation of dyes. Its chemical properties allow for the development of a wide array of dyes with different color characteristics, catering to the needs of various industries.
Used in Fragrance Industry:
4-bromo-2-chloro-6-fluoroBenzonitrile is also used in the production of fragrances, where its reactivity and structural features contribute to the synthesis of unique and complex scent molecules, enriching the perfumery and cosmetic sectors.
Used in Specialty Chemicals:
4-bromo-2-chloro-6-fluoroBenzonitrile's versatility extends to the realm of specialty chemicals, where it is employed in the synthesis of various compounds for specific applications, such as in the coatings, plastics, and materials science industries.
Check Digit Verification of cas no
The CAS Registry Mumber 218797-72-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,7,9 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 218797-72:
(8*2)+(7*1)+(6*8)+(5*7)+(4*9)+(3*7)+(2*7)+(1*2)=179
179 % 10 = 9
So 218797-72-9 is a valid CAS Registry Number.
218797-72-9Relevant articles and documents
Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma
Ensan, Deeba,Smil, David,Zepeda-Velázquez, Carlos A.,Panagopoulos, Dimitrios,Wong, Jong Fu,Williams, Eleanor P.,Adamson, Roslin,Bullock, Alex N.,Kiyota, Taira,Aman, Ahmed,Roberts, Owen G.,Edwards, Aled M.,O'meara, Jeff A.,Isaac, Methvin B.,Al-Awar, Rima
, p. 4978 - 4996 (2020/05/18)
Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention. In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant. Initial efforts resulted in the discovery of M4K2009, an analogue of the previously reported ALK2 inhibitor LDN-214117. Although highly selective for ALK2 over the TGF-βR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel. Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analogue M4K2149 with reduced off-target affinity for the ion channel. Additional modifications yielded 2-fluoro-6-methoxybenzamide derivatives (26a-c), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles.
